Evidence map›Paper›PMID 36863071›Full record

ArticleBiomaterials2023

Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.

Saikat Manna, Sampa Maiti, Jingjing Shen, Adam Weiss, Elizabeth Mulder, Wenjun Du, Aaron P Esser-Kahn

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Nanovaccines empowering CD8Theranostics · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Saikat MannaPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Ave., Chicago, IL 60637, USA.
Sampa MaitiPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Ave., Chicago, IL 60637, USA; Department of Chemistry and Biochemistry, Science of Advanced Material, Central Michigan University, Mount Pleasant, MI 48858, United States.
Jingjing ShenPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Ave., Chicago, IL 60637, USA.
Adam WeissPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Ave., Chicago, IL 60637, USA; Department of Chemistry, University of Chicago, 5735 S Ellis Ave., Chicago, IL 60637, USA.
Elizabeth MulderPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Ave., Chicago, IL 60637, USA.
Wenjun DuDepartment of Chemistry and Biochemistry, Science of Advanced Material, Central Michigan University, Mount Pleasant, MI 48858, United States.
Aaron P Esser-KahnPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Ave., Chicago, IL 60637, USA. Electronic address: aesserkahn@uchicago.edu.
University of Chicago · USCentral Michigan University · US

Funding

Predoctoral Training Program in Chemistry & BiologyT32GM008720 · NIGMS · UNIVERSITY OF CHICAGO · PI PICCIRILLI, JOSEPH ANTHONY · 1999 to 2020
$4.7M
Determining the Molecular Mechanism of Covalently Linked TLR AgonistsU01AI124286 · NIAID · UNIVERSITY OF CHICAGO · PI ESSER-KAHN, AARON P · 2016 to 2020
$3.2M
NIAID NIH HHS U01 AI124286NIGMS NIH HHS T32 GM008720
6 · The paper itself

Abstract

Neoantigen cancer vaccines that target tumor specific mutations are emerging as a promising modality for cancer immunotherapy. To date, various approaches have been adopted to enhance efficacy of these therapies, but the low immunogenicity of neoantigens has hindered clinical application. To address this challenge, we developed a polymeric nanovaccine platform that activates the NLRP3 inflammasome, a key immunological signaling pathway in pathogen recognition and clearance. The nanovaccine is comprised of a poly (orthoester) scaffold engrafted with a small-molecule TLR7/8 agonist and an endosomal escape peptide that facilitates lysosomal rupture and NLRP3 inflammasome activation. Upon solvent transfer, the polymer self-assembles with neoantigens to form ∼50 nm nanoparticles that facilitate co-delivery to antigen-presenting cells. This polymeric activator of the inflammasome (PAI) was found to induce potent antigen-specific CD8

Indexed as

Cancer VaccinesNanoparticlesNeoplasmsAdjuvants, ImmunologicCD8-Positive T-LymphocytesHumansImmunotherapyInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAdjuvants, ImmunologicCancer VaccinesInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAdjuvantBiomaterialsInflammasomeNanovaccineNeoantigen therapy

Identifiers

PMID36863071
PMCPMC10085859
OpenAlexW4321503480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.